ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "Hepatitis C"

  • 2015 American Transplant Congress

    Long-Term Outcome of Liver Transplant Recipients (OLT) With Hepatitis C Recurrence (HCVR) Who Achieved Postoperative Sustained Virologic Response (SVR) After Combination Antiviral Therapy (Rx) With and Without the Use of Telaprevir (TVR): A Single Center Experience

    C. Fasola, P. Mantry, J. Weinstein, H. Nazario, A. Mubarak, M. Barnes, A. Habib, A. Mejia, R. Dickerman, S. Cheng.

    Liver Institute, Methodist Dallas Medical Center, Dallas, TX.

    Aim: Liver allografts of viremic OLT have a higher risk of failure. Timely intervention is necessary. However, long-term outcome reports, especially using newer agents, is…
  • 2015 American Transplant Congress

    Sofosbuvir-Based Therapy for Hepatitis C Recurrence Post Liver Transplantation

    A. Ajlan,1 A. Aljedai,1 H. Elsiesy,2 D. Alkortas,1 R. Alarieh,2 F. Aba Alkhail.2

    1Pharmaceutical Care Division, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia; 2Liver And Small Bowel Trans and Hep/Pancreatic Surgey -Organ Transplant Centre (OTC), King Faisal Specialist Hospital and Research Centre, Riaydh, Saudi Arabia.

    Introduction:Sofosbuvir is approved to treat HCV infection in all genotypes with sustained virological response 12 weeks after completion of therapy (SVR12)rates of up to 100%.…
  • 2015 American Transplant Congress

    Screening Recipients of Increased Risk Donor Organs: A Multicenter Study

    N. Theodoropoulos,1 K. Brizendine,2 M. Ison.3

    1Infectious Diseases, The Ohio State University, Columbus, OH; 2Infectious Disease, Cleveland Clinic, Cleveland, OH; 3Infectious Diseases/Organ Transplantation, Northwestern University, Chicago, IL.

    Purpose: Policy mandates post-transplant (tx) evaluation of recipients of increased risk donor organs (ROIRDO). PHS guidelines recommend that screening include HIV & hepatitis C virus…
  • 2015 American Transplant Congress

    End of Treatment Liver Biopsy With Sofosbuvir: Histologic Changes Suggestive of Hepatitis C Activity in Liver Transplant Recipients With Achieved SVR

    B. Ismail,1 X. Zervos,1 P. Bejarano,2 M. Waton,1 D. Beltran,3 D. Sears,1 A. Tzakis.1

    1Liver Transplant, Cleveland Clinic Florida, Weston, FL; 2Pathology, Cleveland Clinic Florida, Weston, FL; 3Pharmacy, Cleveland Clinic Florida, Weston, FL.

    Background: Interferon (IFN) free HCV regimens are associated with better tolerability and efficacy. The majority of studies report biochemical and virological response; however limited information…
  • 2015 American Transplant Congress

    Safety and Efficacy of All Oral DAA Therapy for Genotype 1 HCV Post-Liver Transplant: Interval Results from the HCV-TARGET Multicenter Prospective Observational Study

    J. O'Leary,1 R. Brown,2 K. Reddy,3 A. Kuo,4 G. Morelli,5 R. Stravitz,6 G. Everson,7 C. Durand,8 H. Vargas,9 P. Kwo,10 C. Frenette,11 J. Peter,12 M. Vainorius,12 L. Akushevich,12 D. Nelson,5 M. Fried,12 N. Terrault.13

    1Baylor University Medical Center, TX; 2Columbia University, NY; 3University of Pennsylvania, PA; 4UCSD, CA; 5University of Florida, Gainesville, Gainesville, FL; 6Virginia Commonwealth University, VA; 7University of Colorado, CO; 8Johns Hopkins, MD; 9Mayo Clinic, AZ; 10Indiana University, IL; 11Scipps Clinic, CA; 12University of North Carolina, NC; 13UCSF, CA.

    The safety and efficacy of direct-acting antivirals (DAA) for HCV post-LT remain unknown. METHODS: We describe the safety and efficacy of all oral DAA-therapy for…
  • 2015 American Transplant Congress

    Sofosbuvir Therapy in Early and Late Post Liver Transplant Setting: A Single Center Experience

    X. Zervos,1 D. Beltran,2 B. Ismail,1 M. Watson,1 D. Sears,1 A. Tzakis.1

    1Liver Transplant, Cleveland Clinic Florida, Weston, FL; 2Pharmacy, Cleveland Clinic Florida, Weston, FL.

    Background: Hepatitis C (HCV) treatment has entered a new phase of excitement with new oral therapies. Here we describe our experience of sofosbuvir (SOF) based…
  • 2015 American Transplant Congress

    Changes in Utilization, Discard, and Outcomes Associated With Hepatitis C (+) Donor Livers in the Era of Direct Acting Anti-Retroviral Therapy

    M. Bowring, L. Kucirka, X. Luo, A. Massie, D. Segev, C. Durand.

    Johns Hopkins University, Baltimore, MD.

    While 45% of liver candidates are hepatitis C (HCV) (+) and might benefit from an HCV (+) donor liver, only 7.1% receive one, and HCV…
  • 2015 American Transplant Congress

    Pretransplant Hepatitis B Viral Infection Increased Risk of Death After Kidney Transplantation

    J. Lee,1 J.-H. Cho,2 J. An,3 C.-D. Kim,2 C. Ahn,4 I. Jung,3 D. Han, C. Lim,3 Y. Kim,4 Y. Kim, J. Lee.3

    1Internal Medicine, Hallym University Hangang Sacred Heart Hospital, Seoul, Republic of Korea; 2Internal Medicine, Kyungpook National University Hospital, Daegu, Republic of Korea; 3Internal Medicine, Seoul National University Boramae Medical Center, Seoul, Republic of Korea; 4Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea; 5Surgery, Ulsan University Seoul Asan Medical Center, Seoul, Republic of Korea.

    Clinical outcomes have not been well evaluated in kidney transplant recipients (KTRs) with hepatitis B virus (HBV). Here, we aimed to investigate the recent posttransplant…
  • 2015 American Transplant Congress

    The Impact of the New Antivirals Sofosfuvir/Ledipasvir on Liver Transplantation for Hepatitis C Cirrhosis

    S. Munoz,1 D. Reich,2 K. Rothstein.1

    1Div of Hepatology, Liver Failure Unit, Hanemann University Hospital, Philadelphia, PA; 2Liver, Kidney and Pancreas Transplant Program, Hahnemann University Hospital, Philadelphia, PA.

    The approval of potent antiviral therapy (AVT) with sofosfuvir/ledipasvir (sof/ldv) for hepatitis C (HCV) dramatically increased cure rates (SVR) to nearly 100%. A recent prospective…
  • 2015 American Transplant Congress

    Pre-Liver Transplant Urinary Proteome Analysis Does Not Predict Development of Chronic Kidney Disease After Transplantation

    D. Milongo,1,3 J. Bascands,2,3,4 L. Esposito,1,3 L. Lavayssière,1,3 A. Del Bello,1,3 L. Rostaing,1,3,5 J. Schanstra,2,3,4 N. Kamar.1,3,5

    1Department of Nephrology and Organ Transplantation, CHU Rangueil, Toulouse, France; 2Institut National de la Santé et de la Recherche Médicale (INSERM), U1048, Institut of Cardiovascular and Metabolic Disease, Toulouse, France; 3Université Toulouse III Paul-Sabatier, Toulouse, France; 4Plateau de Protéomique des Liquides Biologiques, Institut of Cardiovascular and Metabolic Disease, Toulouse, France; 5INSERM U1043, IFR–BMT, Toulouse, France.

    Background and aims: Chronic kidney disease (CKD) is a common complication after liver transplantation. Kidney biopsies cannot be easily performed before liver transplantation to predict…
  • « Previous Page
  • 1
  • …
  • 25
  • 26
  • 27
  • 28
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences